Literature DB >> 17495952

Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression.

Celine Pourreyron1, Georgie Cox, Xin Mao, Andreas Volz, Nuzhat Baksh, Tracy Wong, Hiva Fassihi, Ken Arita, Edel A O'Toole, Jorge Ocampo-Candiani, Mei Chen, Ian R Hart, Leena Bruckner-Tuderman, Julio C Salas-Alanis, John A McGrath, Irene M Leigh, Andrew P South.   

Abstract

Recent data suggest that individuals with recessive dystrophic epidermolysis bullosa (RDEB) only develop squamous-cell carcinoma (SCC) in the presence of the NC1 domain of type VII collagen. This conclusion was based on experimental work in which cryosections of SCCs from 10 people with RDEB all showed positive type VII collagen immunostaining and observations in a murine model of SCC development in which tumors only occurred using keratinocytes from RDEB subjects that expressed detectable levels of the NC1 domain of the type VII collagen protein. To assess whether the clinical interpretation was valid in another cohort of RDEB patients, we examined expression of type VII collagen in 17 SCC tumors excised from 11 patients. Indirect immunofluorescent staining of SCC cryosections and Western blotting of cultured keratinocyte lysates identified two RDEB individuals who did not express detectable levels of type VII collagen. Mutation analysis revealed that these two patients harbor compound heterozygous nonsense mutations within the region of the COL7A1 gene encoding the NC1 domain. These data suggest that individuals with RDEB can develop SCC regardless of type VII collagen expression and that additional factors have a role in explaining the high incidence of tumors complicating this genodermatosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17495952     DOI: 10.1038/sj.jid.5700878

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  11 in total

Review 1.  From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Authors:  Beau R Webber; Jakub Tolar
Journal:  Mol Ther       Date:  2015-03-24       Impact factor: 11.454

2.  [Parallels between wound healing, chronic inflammatory skin diseases and neoplasia: clinical aspects].

Authors:  A Brown; I Tantcheva-Poor; S A Eming
Journal:  Hautarzt       Date:  2014-11       Impact factor: 0.751

Review 3.  Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa.

Authors:  Hye Jin Chung; Jouni Uitto
Journal:  Dermatol Clin       Date:  2010-01       Impact factor: 3.478

4.  Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance.

Authors:  Takenao Chino; Katsuto Tamai; Takehiko Yamazaki; Satoru Otsuru; Yasushi Kikuchi; Keisuke Nimura; Masayuki Endo; Miki Nagai; Jouni Uitto; Yasuo Kitajima; Yasufumi Kaneda
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

5.  Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen.

Authors:  Vera L Martins; Jashmin J Vyas; Mei Chen; Karin Purdie; Charles A Mein; Andrew P South; Alan Storey; John A McGrath; Edel A O'Toole
Journal:  J Cell Sci       Date:  2009-05-12       Impact factor: 5.285

6.  Fludarabine modulates expression of type VII collagen during haematopoietic stem cell transplantation for recessive dystrophic epidermolysis bullosa.

Authors:  M Vanden Oever; D Muldoon; W Mathews; J Tolar
Journal:  Br J Dermatol       Date:  2021-03-08       Impact factor: 11.113

Review 7.  Advances in understanding and treating dystrophic epidermolysis bullosa.

Authors:  Michael J Vanden Oever; Jakub Tolar
Journal:  F1000Prime Rep       Date:  2014-05-06

Review 8.  Risk of Human Papillomavirus Infection in Cancer-Prone Individuals: What We Know.

Authors:  Ruby Khoury; Sharon Sauter; Melinda Butsch Kovacic; Adam S Nelson; Kasiani C Myers; Parinda A Mehta; Stella M Davies; Susanne I Wells
Journal:  Viruses       Date:  2018-01-20       Impact factor: 5.048

Review 9.  Progress toward Treatment and Cure of Epidermolysis Bullosa: Summary of the DEBRA International Research Symposium EB2015.

Authors:  Jouni Uitto; Leena Bruckner-Tuderman; Angela M Christiano; John A McGrath; Cristina Has; Andrew P South; Brett Kopelan; E Clare Robinson
Journal:  J Invest Dermatol       Date:  2016-02       Impact factor: 8.551

10.  Rapid generation of Col7a1-/- mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells.

Authors:  Beau R Webber; Kyle T O'Connor; Ron T McElmurry; Elise N Durgin; Cindy R Eide; Christopher J Lees; Megan J Riddle; Wendy E Mathews; Natasha Y Frank; Mark A Kluth; Christoph Ganss; Branden S Moriarity; Markus H Frank; Mark J Osborn; Jakub Tolar
Journal:  Lab Invest       Date:  2017-09-11       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.